NOVAVAX ($NVAX) posted quarterly earnings results for Q1 2026 on Wednesday, May 6th. The company reported earnings of -$0.06 per share, beating estimates of -$0.23 by $0.17. The company also reported revenue of $139,510,000, beating estimates of $79,889,286 by $59,620,714.
You can see Quiver Quantitative's $NVAX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
NOVAVAX Hedge Fund Activity
We have seen 105 institutional investors add shares of NOVAVAX stock to their portfolio, and 124 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANK OF AMERICA CORP /DE/ added 5,189,591 shares (+167.3%) to their portfolio in Q4 2025, for an estimated $34,874,051
- COATUE MANAGEMENT LLC removed 3,836,986 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $25,784,545
- MORGAN STANLEY added 2,641,540 shares (+245.4%) to their portfolio in Q4 2025, for an estimated $17,751,148
- MILLENNIUM MANAGEMENT LLC added 2,342,804 shares (+110.1%) to their portfolio in Q4 2025, for an estimated $15,743,642
- STATE STREET CORP added 2,326,927 shares (+32.3%) to their portfolio in Q4 2025, for an estimated $15,636,949
- D. E. SHAW & CO., INC. added 1,718,719 shares (+40.2%) to their portfolio in Q4 2025, for an estimated $11,549,791
- RENAISSANCE TECHNOLOGIES LLC removed 1,196,750 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $8,042,160
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
NOVAVAX Analyst Ratings
Wall Street analysts have issued reports on $NVAX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 01/20/2026
- JP Morgan issued a "Underweight" rating on 11/18/2025
- B. Riley Securities issued a "Buy" rating on 11/10/2025
To track analyst ratings and price targets for NOVAVAX, check out Quiver Quantitative's $NVAX forecast page.
NOVAVAX Price Targets
Multiple analysts have issued price targets for $NVAX recently. We have seen 4 analysts offer price targets for $NVAX in the last 6 months, with a median target of $16.0.
Here are some recent targets:
- Sean Lee from HC Wainwright & Co. set a target price of $16.0 on 02/27/2026
- Thomas Shrader from BTIG set a target price of $19.0 on 01/20/2026
- Anupam Rama from JP Morgan set a target price of $6.0 on 11/18/2025
- Mayank Mamtani from B. Riley Securities set a target price of $16.0 on 11/10/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
